source
- Schrödinger launches AI agent Bunsen, CEO admits earlier AI skepticism was wrongSchrödinger announced the debut of its new AI agent, Bunsen, which is built on the company’s physics‑based software platform. The tool is intended to help biopharma researchers model molecular beha…
- Apnimed targets up to $160 million IPO to fund launch of Oxnimbi, its oral sleep apnea pillApnimed, a Massachusetts biotech, filed with the SEC indicating it will seek an IPO of up to $160 million to finance the commercial launch of its oral obstructive sleep apnea therapy, Oxnimbi (AD10…